Debra Aron is speaking at the lecture to discuss the “ins and outs” of the qualitative elements for evaluating an alleged antitrust violation.
For more information on this event, click here.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...

